This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): IMA-638, PF-05230917
Description: Anrukinzumab is a humanized mouse monoclonal antibody to human IL-13. Preclinical studies suggest that IL-13 is a key mediator of asthma responses, including airway inflammation, obstruction and hyper-reactivity.
Deal Structure: Anrukinzumab was originally developed by Wyeth.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.
Pink Sheet Pfizer & Wyeth: A Pipeline Two-Deep
Additional information available to subscribers only: